Power Law company profile

Immunai

Biotech & Life Sciences · New York City, United States · Founded 2019 Unicorn

Mapping and reprogramming the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development, and improve patient outcomes

Valuation

$1–2.5B

Latest valuation · 2026

Unlock exact value

Headcount

100–500

Current team size

Unlock exact value

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026

Investors

12 investors on Immunai's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 2 investors entered at this stage

Viola Ventures

TLV Partners

Series A 4 investors entered at this stage

Dexcel Pharma

Catalio Capital Management

Schusterman Foundation

Duquesne Family Office

Series B+ 6 investors entered at this stage

Piedmont Healthcare

Koch Disruptive Technologies

Alexandria Venture Investments

Icon Ventures

Talos

8VC

Immunai mafia

Startups founded by Immunai alumni

Former Immunai employees who went on to start their own companies. Sorted by Dealroom signal score.

PhaseVEst. 2023

Raviv PrylukIsrael

Signal score93

DermagnostixEst. 2021

Fabian TheisGermany

Signal score84

Santa Ana BioEst. 2021

Ansuman SatpathyUnited States

Signal score67

Jimini HealthEst. 2023

Mark JacobsteinUnited States

Signal score58

Book a demo to explore the full alumni network →

Global footprint

Where Immunai has talent and traffic

AI talent share

11.1% of workforce is AI talent
(20 of 180 staff)

Core AI116.11%

Other AI95%

Non-AI workforce16088.89%

Workforce by country

8 countries with
team presence

🇮🇱 Israel42%

🇺🇸 United States39.4%

🇨🇿 Czech Republic12%

🇨🇭 Switzerland3.9%

🇩🇪 Germany1.1%

Top 5 of 8 shown

Web traffic by country

7.1K monthly visits
across markets

🇺🇸 United States76.1%

🇨🇦 Canada9.9%

🇨🇿 Czech Republic7%

🇯🇵 Japan5.6%

🇩🇪 Germany0%

Top 5 markets shown

Patent intelligence

$90k patent portfolio · 3 active families

Estimated portfolio value

$90k

<0.01% of valuation · 8688.9× smaller than top peer BioNTech ($780M)

3 active patent families

Where Immunai innovates Molecular biologyMarker genePlasma lipidsHepatic lipidGene

Where Immunai concentrates vs peers

Each axis is a top-10 topic across Immunai and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Immunai

An AI-synthesized read of the highest-engagement posts about Immunai on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Immunai on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles